Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 2 hours ago
ASCO, Ryght AI team up for breast cancer trial site selection
about 2 hours ago
The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming...
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
about 6 hours ago
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has...
Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
about 6 hours ago
Rallybio has steered its way to a new reverse merger, inking a...
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
about 7 hours ago
Servier has struck a deal to buy Edgewise Therapeutics’ muscular dystrophy business...
Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
about 8 hours ago
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli...
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
about 11 hours ago
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction...
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
1 day ago
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline...
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
1 day ago
This year’s meeting of the American Society of Clinical Oncology is abuzz...
ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
1 day ago
Kelonia Therapeutics has shared the largest slice of data yet for an...
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
2 days ago
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies...
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
2 days ago
The German biotech shared updated data from a phase 1 study of...
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
3 days ago
Nine years after wowing the audience at the American Society of Clinical...